Supernus Pharmaceuticals (NASDAQ:SUPN) Stock Dropped to “Strong Sell” by Zacks Research

Zacks Research cut shares of Supernus Pharmaceuticals (NASDAQ:SUPN) from a hold rating to a strong sell rating in a research note issued to investors on Monday morning,Zacks reports.

A number of other research firms also recently weighed in on SUPN. Weiss Ratings restated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Monday, September 21st. Cantor Fitzgerald upped their price objective on shares of Supernus Pharmaceuticals from $63.00 to $67.00 and gave the stock an “overweight” rating in a research report on Thursday, July 9th. Finally, Wall Street Zen lowered shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $62.83.

Supernus Pharmaceuticals Stock Performance

Supernus Pharmaceuticals stock opened at $42.83 on Monday. Supernus Pharmaceuticals has a 52 week low of $40.51 and a 52 week high of $59.68. The stock has a market capitalization of $2.49 billion, a P/E ratio of -22.31, a price-to-earnings-growth ratio of 0.79 and a beta of 0.55. The stock has a fifty day moving average of $44.49 and a 200-day moving average of $46.83.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings data on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of $0.42 by ($1.43). Supernus Pharmaceuticals had a negative net margin of 13.23% and a positive return on equity of 11.13%. The business had revenue of $219.06 million during the quarter, compared to analyst estimates of $205.31 million. During the same period last year, the business earned $0.40 earnings per share. The business’s quarterly revenue was up 32.4% compared to the same quarter last year. On average, research analysts forecast that Supernus Pharmaceuticals will post 1.97 earnings per share for the current year.

Institutional Trading of Supernus Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of SUPN. Sit Investment Associates Inc. raised its stake in shares of Supernus Pharmaceuticals by 0.4% in the 4th quarter. Sit Investment Associates Inc. now owns 65,200 shares of the specialty pharmaceutical company’s stock valued at $3,240,000 after acquiring an additional 250 shares in the last quarter. Summit Global Investments boosted its holdings in Supernus Pharmaceuticals by 6.1% in the 1st quarter. Summit Global Investments now owns 4,436 shares of the specialty pharmaceutical company’s stock valued at $229,000 after purchasing an additional 256 shares during the period. PNC Financial Services Group Inc. lifted its stake in shares of Supernus Pharmaceuticals by 2.3% in the first quarter. PNC Financial Services Group Inc. now owns 14,548 shares of the specialty pharmaceutical company’s stock valued at $752,000 after buying an additional 321 shares during the period. Corient Private Wealth LP grew its position in Supernus Pharmaceuticals by 6.6% during the second quarter. Corient Private Wealth LP now owns 5,163 shares of the specialty pharmaceutical company’s stock worth $240,000 after buying an additional 321 shares in the last quarter. Finally, Juncture Wealth Strategies LLC increased its stake in Supernus Pharmaceuticals by 5.8% during the third quarter. Juncture Wealth Strategies LLC now owns 6,778 shares of the specialty pharmaceutical company’s stock valued at $292,000 after acquiring an additional 374 shares during the period.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing treatments for diseases of the central nervous system (CNS). The company’s portfolio has primarily addressed epilepsy, attention-deficit/hyperactivity disorder (ADHD), and other neurological conditions, with an emphasis on differentiated formulations and products designed to improve treatment convenience and patient outcomes.

Supernus markets Oxtellar XR (oxcarbazepine extended-release) for the treatment of partial-onset seizures and Trokendi XR (topiramate extended-release) for certain seizure disorders and the prevention of migraine headaches.